Flezelastine
Alternative Names: D 18024; IDB 18024Latest Information Update: 20 Jan 2017
At a glance
- Originator ASTA Medica [CEASED]
- Developer ASTA Medica; ASTA Medica [CEASED]; Meda Pharmaceuticals; MedPointe; National Cancer Institute (USA); Nonindustrial source
- Class Antiallergics; Antiasthmatics; Antihistamines; Azepines; Phthalazines
- Mechanism of Action 5-lipoxygenase inhibitors; Calcium channel antagonists; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma; Cancer
Most Recent Events
- 20 Jan 2017 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 20 Jan 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 11 Sep 1998 Discontinued-Preclinical in Cancer in Germany (Unknown route)